Royalty Pharma (RPRX) PT Raised to $38 at UBS, But Firm on Sidelines Due to Structural Issues

UBS analyst Ashwani Verma raised the price target on Royalty Pharma (NASDAQ: RPRX) to $38.00 (from $37.00) while maintaining a Neutral rating.

The analyst commented, "Post RP's Investor Day, we continue to remain on the sidelines for the stock as we see structural issues in the equity story. While the business fundamentals continue to be strong, stock is likely to outperform in our view...Our PT increases to $38 (from $37), based on an unchanged 10x EV/EBITDA multiple and a slightly increased 2026 EBITDA estimate of $3.06bn (prior $3.02bn), reflecting the inclusion of newly added royalty deals (w/ Amgen and Zenas) as well as the recent debt offering."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• Full Circle Lithium closes $5.14M private placement